Cargando…
1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808722/ http://dx.doi.org/10.1093/ofid/ofz360.1643 |
_version_ | 1783461804389695488 |
---|---|
author | Njue, Annete Marguilis, Andrea Lyall, Matthew Nuabor, Weyinmi Marks, Morgan Russell, Kevin Sinha, Anushua |
author_facet | Njue, Annete Marguilis, Andrea Lyall, Matthew Nuabor, Weyinmi Marks, Morgan Russell, Kevin Sinha, Anushua |
author_sort | Njue, Annete |
collection | PubMed |
description | BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines or public health authorities, but is conducted on an opportunistic basis by specific healthcare systems and providers. This targeted review describes the rate of reported maternal screening for CMV infection and subsequent pregnancy outcomes. METHODS: PubMed and Embase were searched to identify English-language articles reporting the rate of screening for CMV maternal infection (Objective 1), the acceptance rate for diagnostic amniocentesis (Objective 2), and the elective termination rates due to CMV infection (Objective 3) in Europe and Israel. No date limit was applied. RESULTS: Seventeen articles published between 2000 and 2018 were included. Routine CMV screening of pregnant women in the absence of country-level guidelines appears to be common in France and Israel (table). Conversely, in Portugal, where country-level guidelines exist for preconception screening, a high proportion of women are not screened (table). Acceptance rates of diagnostic amniocentesis among women with CMV infection vary considerably across countries, with the highest rates reported in Israel (73%) and the lowest in Italy (16%). Elective termination rates were higher among women who underwent amniocentesis vs. those who did not and those with primary CMV infection vs. those with nonprimary infection. Conversely, one study in Israel showed higher termination rates among patients who did not undergo amniocentesis vs. those who did (35.5% vs. 7.3%). CONCLUSION: The available data indicate that routine screening is carried out in some countries to a variable degree. There is an unmet need for effective prevention and management options to help prevent unnecessary termination of pregnancy. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6808722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68087222019-10-28 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? Njue, Annete Marguilis, Andrea Lyall, Matthew Nuabor, Weyinmi Marks, Morgan Russell, Kevin Sinha, Anushua Open Forum Infect Dis Abstracts BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines or public health authorities, but is conducted on an opportunistic basis by specific healthcare systems and providers. This targeted review describes the rate of reported maternal screening for CMV infection and subsequent pregnancy outcomes. METHODS: PubMed and Embase were searched to identify English-language articles reporting the rate of screening for CMV maternal infection (Objective 1), the acceptance rate for diagnostic amniocentesis (Objective 2), and the elective termination rates due to CMV infection (Objective 3) in Europe and Israel. No date limit was applied. RESULTS: Seventeen articles published between 2000 and 2018 were included. Routine CMV screening of pregnant women in the absence of country-level guidelines appears to be common in France and Israel (table). Conversely, in Portugal, where country-level guidelines exist for preconception screening, a high proportion of women are not screened (table). Acceptance rates of diagnostic amniocentesis among women with CMV infection vary considerably across countries, with the highest rates reported in Israel (73%) and the lowest in Italy (16%). Elective termination rates were higher among women who underwent amniocentesis vs. those who did not and those with primary CMV infection vs. those with nonprimary infection. Conversely, one study in Israel showed higher termination rates among patients who did not undergo amniocentesis vs. those who did (35.5% vs. 7.3%). CONCLUSION: The available data indicate that routine screening is carried out in some countries to a variable degree. There is an unmet need for effective prevention and management options to help prevent unnecessary termination of pregnancy. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808722/ http://dx.doi.org/10.1093/ofid/ofz360.1643 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Njue, Annete Marguilis, Andrea Lyall, Matthew Nuabor, Weyinmi Marks, Morgan Russell, Kevin Sinha, Anushua 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title | 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title_full | 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title_fullStr | 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title_full_unstemmed | 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title_short | 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? |
title_sort | 1780. congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808722/ http://dx.doi.org/10.1093/ofid/ofz360.1643 |
work_keys_str_mv | AT njueannete 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT marguilisandrea 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT lyallmatthew 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT nuaborweyinmi 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT marksmorgan 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT russellkevin 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination AT sinhaanushua 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination |